Kyowa Hakko Kirin To Resume Development Of Kidney Disease Drug Bardoxolone Methyl In Japan
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko Kirin will restart its Phase II trials with bardoxolone methyl for the treatment of chronic kidney disease in type 2 diabetes patients, the company announced on July 2.
You may also be interested in...
Outlook For Reata's Bardoxolone Improves With Phase II Updates
Latest data support moving bardoxolone into Phase III for autosomal dominant polycystic kidney disease (ADPKD).
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.